US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Orano Med

News headline image
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha Therapies
From Orano Med
Via Business Wire
News headline image
Orano Med Provides Half-Year Progress Report and Business Outlook
From Orano Med
Via Business Wire
News headline image
Three New Independent Members Join Orano Med’s Governing Board
From Orano Med
Via Business Wire
News headline image
The European Investment Bank Grants Orano a Loan of €125 Million to Finance Orano Med’s Innovations and Industrial Infrastructure
From Orano Med
Via Business Wire
News headline image
Orano Announces the Appointment of Frederic Desdouits as CEO of Orano Med
From Orano Med
Via Business Wire
News headline image
Orano Med Enters Next Phase of Collaboration With Roche
From Orano Med
Via Business Wire
News headline image
Orano Med Achieves Key Milestone in French ATEF Facility Construction, an Essential Asset for Large-Scale Production of Innovative Lead-212-based Therapies
From Orano Med
Via Business Wire
News headline image
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
From Orano Med
Via Business Wire
News headline image
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors
From Orano Med
Via Business Wire
News headline image
RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers
From Orano Med
Via Business Wire
News headline image
Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
From Orano Med
Via Business Wire